Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13757232 | 0.73 | MAPK1 (0.34) | ELANEMAPK1HSD17B10 | |
| SCHEMBL12962743 | 0.67 | — | — | |
| SCHEMBL1060667 | 0.66 | ALDH1A1 (0.39) | KDM4EHSD17B10 | |
| SCHEMBL1062886 | 0.65 | HSD17B10 (0.43) | KDM4EHSD17B10 | |
| SCHEMBL13757219 | 0.61 | MAPK1 (0.34) | ELANEMAPK1HSD17B10 | |
| SCHEMBL13410110 | 0.61 | MAPK1 (0.58) | KDM4EMAPK1HSD17B10 | |
| SCHEMBL8240581 | 0.60 | MAPK1 (0.37) | ELANEKDM4EMAPK1HSD17B10 | |
| SCHEMBL16284922 | 0.60 | NOS1 (0.33) | — | |
| SCHEMBL16575414 | 0.60 | NQO1 (0.40) | KDM4EHSD17B10 | |
| SCHEMBL257133 | 0.59 | NOS1 (0.39) | ELANEKDM4EMAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217176-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20090227561-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227561-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | SMO, NR1H2, NR1H4 | ELANE 4650/4885KDM4E 464/4885MAPK1 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.